Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY23 results · Jan–Mar 2023
Suven Life Sciences reported revenue from operations of ₹2.61 crore (down 38.1% from Q4 FY22) and net loss of ₹27.64 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.61 | 4.22 | −38.1% | 3.00 | −13.0% |
| Other income | 5.60 | 0.12 | 47x | 2.20 | +154.1% |
| Total income | 8.21 | 4.34 | +89.3% | 5.21 | +57.7% |
| Profit before tax | (27.64) | (20.80) | Loss widened | (51.12) | Loss narrowed |
| Net profit for the period | (27.64) | (20.80) | Loss widened | (51.12) | Loss narrowed |
| EPS, basic (₹) | (1.17) | (1.63) | not comparable | (2.90) | Loss narrowed |
| Net margin (%) | -1058.7 | -492.7 | -1702.5 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.61 | 4.22 | −38.1% | 3.00 | −13.0% |
| Other income | 5.60 | 0.12 | 47x | 2.20 | +154.1% |
| Total income | 8.21 | 4.34 | +89.3% | 5.21 | +57.7% |
| Profit before tax | (2.25) | (8.55) | Loss narrowed | (6.63) | Loss narrowed |
| Net profit for the period | (2.25) | (8.55) | Loss narrowed | (6.63) | Loss narrowed |
| EPS, basic (₹) | (0.05) | (0.67) | not comparable | (0.35) | Loss narrowed |
| Net margin (%) | -86.1 | -202.6 | -220.9 |
Consolidated
- Filed with BSE
- 16 May 2023, 16:05 IST
- Board meeting
- 09 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 May 2023, 16:05 IST
- Board meeting
- 09 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE